Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial
      QxMD      Google Scholar   
Citation:
Ann. Oncol vol 28 (5) 1070-77
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
DataSharing:
No
Book Volume:
6
Parents:
2360   2504  
Children:
None
Program:
TRP
Primary Committee:
PPP
Sec. Committees:
Breast    
Pharmas:
 
Grants:
K22CA188163, U10CA025224, U10CA037347, U10CA037404, U10CA047577, U10CA076001, U10CA077440, U10CA180790, U10CA180833, U10CA180857, U10CA180858, U10CA180870, U10CA180821, U10CA180882, U54HG003079  
Corr. Author:
 
Authors:
                                   
Primary Study
ACOSOG-Z1041
Secondary Studies:
Phases:
3
Keywords: